Next Article in Journal
Caught in the Middle: Case Study of a Brachial (Sentry) Lymph Node Recurrence after Resection and Locoregional Breast Radiotherapy
Previous Article in Journal
Moderators of Psychological Recovery from Benign Cancer Screening Results
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 3
10.3747/co.19.915
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Quality-of-Life Outcomes in High-Risk Prostate Cancer Patients Treated with Helical Tomotherapy in a Hypofractionated Radiation Schedule with Long-Term Androgen Suppression

by
N. Pervez
1,*,
A.V. Krauze
1,
D. Yee
1,
M. Parliament
1,
A. Mihai
1,
S. Ghosh
1,
K. Joseph
1,
A. Murtha
1,
J. Amanie
,
M. Kamal
2 and
R. Pearcey
1
1
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
2
Univ Coll Dublin, Dublin 2, Ireland
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(3), 201-210; https://doi.org/10.3747/co.19.915
Submission received: 2 March 2012 / Revised: 4 April 2012 / Accepted: 6 May 2012 / Published: 1 June 2012

Abstract

Purpose: We examined the impact of hypofractionated radiation therapy and androgen suppression therapy (AST) on quality of life (QOL) in high-risk prostate cancer patients. Methods: Between March 2005 and March 2007, 60 patients with high-risk prostate cancer were enrolled in a prospective phase ii study. All patients received 68 Gy (2.72 Gy per fraction) to the prostate gland and 45 Gy (1.8 Gy per fraction) to the pelvic lymph nodes in 25 fractions over 5 weeks. Of the 60 patients, 58 received AST. The University of California–Los Angeles Prostate Cancer Index questionnaire was used to prospectively measure qol at baseline (month 0) and at 1, 6, 12, 18, 24, 30, and 36 months after radiation treatment. The generalized estimating equation approach was used to compare the QOL scores at 1, 6, 12, 18, 24, 30, and 36 months with those at baseline. Results: We observed a significant decrease in QOL items related to bowel and sexual function. Several QOL items related to bowel function were significantly adversely affected at both 1 and 6 months, with improvement toward 6 months. Although decreased QOL scores persisted beyond the 6-month mark, they began to re-approach baseline at the 18- to 24-month mark. Most sexual function items were significantly adversely affected at both 1 and 6 months, but the effects were not considered to be a problem by most patients. A complete return to baseline was not observed for either bowel or sexual function. Urinary function items remained largely unaffected, with overall urinary function being the only item adversely affected at 6 months, but not at 1 month. Urinary function returned to baseline and remained unimpaired from 18 months onwards. Conclusions: In our study population, who received hypofractionated radiation delivered using dynamic intensity-modulated radiotherapy with inclusion of the pelvic lymph nodes, and 2–3 years of AST prescription, QOL with respect to bowel and sexual function was significantly affected; QOL with respect to urinary function was largely unaffected. Our results are comparable to those in other published studies.
Keywords: prostate cancer; quality of life; hypofractionation; imrt; toxicity; ast prostate cancer; quality of life; hypofractionation; imrt; toxicity; ast

Share and Cite

MDPI and ACS Style

Pervez, N.; Krauze, A.V.; Yee, D.; Parliament, M.; Mihai, A.; Ghosh, S.; Joseph, K.; Murtha, A.; Amanie, J.; Kamal, M.; et al. Quality-of-Life Outcomes in High-Risk Prostate Cancer Patients Treated with Helical Tomotherapy in a Hypofractionated Radiation Schedule with Long-Term Androgen Suppression. Curr. Oncol. 2012, 19, 201-210. https://doi.org/10.3747/co.19.915

AMA Style

Pervez N, Krauze AV, Yee D, Parliament M, Mihai A, Ghosh S, Joseph K, Murtha A, Amanie J, Kamal M, et al. Quality-of-Life Outcomes in High-Risk Prostate Cancer Patients Treated with Helical Tomotherapy in a Hypofractionated Radiation Schedule with Long-Term Androgen Suppression. Current Oncology. 2012; 19(3):201-210. https://doi.org/10.3747/co.19.915

Chicago/Turabian Style

Pervez, N., A.V. Krauze, D. Yee, M. Parliament, A. Mihai, S. Ghosh, K. Joseph, A. Murtha, J. Amanie, M. Kamal, and et al. 2012. "Quality-of-Life Outcomes in High-Risk Prostate Cancer Patients Treated with Helical Tomotherapy in a Hypofractionated Radiation Schedule with Long-Term Androgen Suppression" Current Oncology 19, no. 3: 201-210. https://doi.org/10.3747/co.19.915

APA Style

Pervez, N., Krauze, A. V., Yee, D., Parliament, M., Mihai, A., Ghosh, S., Joseph, K., Murtha, A., Amanie, J., Kamal, M., & Pearcey, R. (2012). Quality-of-Life Outcomes in High-Risk Prostate Cancer Patients Treated with Helical Tomotherapy in a Hypofractionated Radiation Schedule with Long-Term Androgen Suppression. Current Oncology, 19(3), 201-210. https://doi.org/10.3747/co.19.915

Article Metrics

Back to TopTop